• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

More Data on Hormone Therapy and Breast Cancer Risk

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Vinogradova et al. (BMJ, 2020) examined the risk of breast cancer associated with different types and durations of hormone replacement therapy (HRT)

METHODS:

  • Two nested case-control studies
  • Data source
    • 2 of the largest UK primary care databases: QResearch and Clinical Practice Research Datalink (CPRD) GOLD
  • Participants
    • Women age 50 to 79
    • Primary diagnosis of breast cancer between 1998 and 2018
    • Female controls: Matched by age, general practice, and index date
  • Study design
    • Definitions
      • Recent use: <5 years
      • Long-term use: ≥5 years
      • Short-term use: <4 years
    • Odds ratio (OR) calculated for HRT types, adjusted for personal characteristics, smoking status, alcohol consumption, comorbidities, family history, and other prescribed drugs
  • Primary outcome
    • Breast cancer diagnosis from general practice, mortality, hospital or cancer registry records

RESULTS:

  • 98,611 women with breast cancer | 457,498 controls
  • Use of HRT prior to one year before the index date
    • Women with breast cancer: 34%
    • Control Group: 31%
  • Estrogen-only therapy and combined estrogen and progestogen therapy were both associated with increased risks of breast cancer in recent users with long-term use, compared with women who never used HRT
    • Estrogen-only: adjusted OR 1.15 (95% CI, 1.09 to 1.21)
    • Combined: 1.79 (95% CI, 1.73 to 1.85)
  • For combined progestogens, the increased risk was highest for norethisterone and lowest for dydrogesterone
    • Norethisterone: aOR 1.88 (95% CI, 1.79 to 1.99)
    • Dydrogesterone: aOR 1.24 (95% CI, 1.03 to 1.48)
  • Past use
    • Past long-term use of estrogen-only therapy and past short-term use of estrogen-progestogen were not associated with increased risk
    • Past long-term estrogen-progestogen use was still associated with increased risk
      • Estrogen-progestogen: aOR 1.16 (95% CI, 1.11 to 1.21)
  • Extra expected cases in HRT users
    • Recent estrogen-only: Between 3 (in younger women) and 8 (in older women) extra cases per 10,000-person years
    • Recent estrogen-progestogen: Between 9 and 36 extra cases per 10,000-person years
    • Past estrogen-progestogen: Between 2 and 8 extra cases per 10,000-person years

CONCLUSION:

  • In this study, women who used combined methods of HRT, and women who used HRT for longer, had an increased risk of breast cancer
  • Past long-term use of estrogen-only therapy and past short-term use of estrogen-progestogen were not associated with increased risk
  • The authors conclude

Our findings of generally lower increased risks for combined HRT treatments and of more pronounced declines in risk once HRT has stopped, provide some counterbalance to the higher than expected risks reported in a recently published meta-analysis

Learn More – Primary Sources:

Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

North American Menopause Society: Hormone Therapy Statement
The WHI Randomized Trials: Is Menopausal Hormone Therapy Associated with Long-Term Mortality?
Prospective Data: Breast Cancer Risk and Menopausal Hormone Therapy
Is There an Association Between Vaginal Estrogen Use and Risk for Cardiovascular Disease and Cancer?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site